# rhBNP in Type 3 Pulmonary Hypertension

> **NCT05716984** · PHASE4 · UNKNOWN · sponsor: **Shengjing Hospital** · enrollment: 72 (estimated)

## Conditions studied

- Group 3 Pulmonary Hypertension

## Interventions

- **DRUG:** recombinant human brain natriuretic peptide
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05716984
- **Lead sponsor:** Shengjing Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-04-15
- **Primary completion:** 2023-12-31
- **Final completion:** 2024-03-30
- **Target enrollment:** 72 (ESTIMATED)
- **Last updated:** 2023-10-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05716984

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05716984, "rhBNP in Type 3 Pulmonary Hypertension". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT05716984. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*